Uplizna reduces several subsets of immune B-cells that are linked to relapses in people with neuromyelitis optica spectrum disorder, data show.| Neuromyelitis News
Regular rituximab treatment in neuromyelitis optica spectrum disorder resulted in less disability and fewer relapses, per a real word study.| Neuromyelitis News
Nearly all neuromyelitis optica spectrum disorder patients on Enspryng remain free from relapses after six months, a real-world study in Japan shows.| Neuromyelitis News
NMOSD patients who are positive for the anti-AQP4 antibodies were more likely to have other autoimmune diseases, a study in Argentina shows.| Neuromyelitis News
A new predictive model to identify neuromyelitis optica spectrum disorder patients at a higher risk of relapse was found accurate in a study.| Neuromyelitis News